Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Gets More Time for Nasdaq Compliance

NEW YORK (GenomeWeb News) – Nanogen said in a filing with the US Securities and Exchange Commission today that it now has until May 27 to regain compliance with Nasdaq's $1 minimum bid price listing requirement.

Nanogen was notified in May 2008 that it was not in compliance with the minimum bid rule, and the firm had until the end of November to regain compliance. However, in October, due to the suspension by Nasdaq of certain listing requirements, Nanogen was given until Feb. 26 to regain compliance.

On Dec. 19, 2008, Nasdaq extended the temporary suspension of the minimum bid price requirement until April 20, 2009, on which date the rules will be reinstated. This extension means that Nanogen will now have until May 27 to regain compliance. The firm's share price must close at $1 for a minimum of 10 consecutive trading days for it to meet listing requirements.

Nanogen closed Tuesday at $.18 per share. Its shares have not traded above $1 since Oct. 30, 2007.

Filed under

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more